Welcome to LookChem.com Sign In|Join Free
  • or
3-(1H-benzo[d]imidazol-2-yl)-4-methoxybenzaldehyde is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

628710-87-2

Post Buying Request

628710-87-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

628710-87-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 628710-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,8,7,1 and 0 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 628710-87:
(8*6)+(7*2)+(6*8)+(5*7)+(4*1)+(3*0)+(2*8)+(1*7)=172
172 % 10 = 2
So 628710-87-2 is a valid CAS Registry Number.

628710-87-2Downstream Products

628710-87-2Relevant academic research and scientific papers

Suzuki-miyaura cross-coupling of unprotected, nitrogen-rich heterocycles: Substrate scope and mechanistic investigation

Duefert, M. Alexander,Billingsley, Kelvin L.,Buchwald, Stephen L.

supporting information, p. 12877 - 12885 (2013/09/23)

The Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles using precatalysts P1 or P2 is reported. The procedure allows for the reaction of variously substituted indazole, benzimidazole, pyrazole, indole, oxindole, and azaindole halides under mild conditions in good to excellent yields. Additionally, the mechanism behind the inhibitory effect of unprotected azoles on Pd-catalyzed cross-coupling reactions is described based on evidence gained through experimental, crystallographic, and theoretical investigations.

CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES

-

Page 50-51, (2008/06/13)

The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 628710-87-2